Science and Health News

Imugene Limited (ASX:IMU), a clinical-stage immuno-oncology company, and City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced that the first patient was dosed in a Phase 1 clinical trial evaluating the safety of novel cancer-killing virus CF33-hNIS VAXINIA when used in people with advanced solid tumors. The City of Hope-developed oncolytic virus has been shown to shrink colon, lung, breast, ovarian and pancreatic cancer tumors in preclinical laboratory and animal models.

In mouse studies, pain-blocking neurotransmitters produced long-lasting benefit without detectable side effects

First Successful Treatment of Mycobacterial Lung Infection with Bacteriophages

Australia recently passed legislation explicitly allowing mitochondrial donation (see BioNews 1139). It is the second country after the UK to do so (see BioNews 826). Like in the UK, the technique is only allowed to prevent transmission of mitochondrial defects in children of mothers known to be carriers of such diseases.

QUT genetic researchers have found blood proteins that cause migraine and have a shared link with Alzheimer’s disease that could potentially be prevented by repurposing existing therapeutics.

By restoring the light-sensing function of human retinas hours after death, Scripps Research and collaborators reveal a new way to study age-related macular degeneration and other eye disorders.

Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that Prof. Matthias Liechti and Dr. Friederike Holze, MindMed collaborators at University Hospital Basel (UHB), have released positive topline data from a Phase 2 placebo-controlled investigator-initiated clinical trial evaluating LSD in the treatment of anxiety disorders.

Research showed microbiome may be used to track impact of injuries and recovery timeline